Abstract
Switzerland has one of the highest annual Legionnaires’ disease (LD) notification rates in Europe (7.8 cases/ 100,000 population in 2021). The main sources of infection and the cause for this high rate remain largely unknown. This hampers the implementation of targeted Legionella spp. control efforts. The SwissLEGIO national case-control and molecular source attribution study investigates risk factors and infection sources for community-acquired LD in Switzerland. Over the duration of one year, the study is recruiting 205 newly diagnosed LD patients through a network of 20 university and cantonal hospitals. Healthy controls matched for age, sex, and residence at district level are recruited from the general population. Risk factors for LD are assessed in questionnaire-based interviews. Clinical and environmental Legionella spp. isolates are compared using whole genome sequencing (WGS). Direct comparison of sero- and sequence types (ST), core genome multilocus sequencing types (cgMLST), and single nucleotide polymorphisms (SNPs) between clinical and environmental isolates are used to investigate infection sources and the prevalence and virulence of different Legionella spp. strains detected across Switzerland. The SwissLEGIO study innovates in combining case-control and molecular typing approaches for source attribution on a national level outside an outbreak setting. The study provides a unique platform for national Legionellosis and Legionella research and is conducted in an inter- and transdisciplinary, co-production approach involving various national governmental and national research stakeholders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The SwissLEGIO project is funded by the Federal Office of Public Health (FOPH, grant nr.: 142004673). For the molecular source attribution we acknowledge financial support from the Federal Food Safety and Veterinary Office, the FOPH and the Federal Office of Energy through the project LeCo (Legionella Control in Buildings; Aramis nr.: 4.20.01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Commission of Northwestern and Central Switzerland gave ethical approval for this work (nr.: 2022-00880).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵£ List of hospital network partners: Isabel Akers (Spital Limmattal, Zürich-Schlieren, Switzerland), Werner C. Albrich (Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland), Diane Bandeira (Microbiology Laboratory, Cantonal Hospital of Fribourg HFR, Fribourg, Switzerland), Enos Bernasconi (Ospedale Regionale di Lugano EOC, Lugano, Switzerland; University of Geneva, Genève, Switzerland; University of Southern Switzerland, Lugano, Switzerland), Delphine Berthod (Infectious Diseases Department, Central Institute of Hospitals, Sion, Switzerland), Maria Boesing (Medizinische Fakultät Universität Basel, Basel, Switzerland; Medizinische Universitätsklinik Kantonsspital Baselland, Liestal, Switzerland), Romana Calligaris-Maibach (Zentrallabor Mikrobiologie, Kantonsspital Baden, Baden, Switzerland), Olivier Clerc (Réseau Hospitalier Neuchâtelois, Neuchâtel, Switzerland), Antony Croxatto (ADMED Microbiology, La Chaux-de-Fonds, Switzerland), Vanessa Deggim-Messmer (Microbiology Laboratory, Cantonal Hospital of Fribourg HFR, Fribourg, Switzerland), Sarah Dräger (Division of Internal Medicine, University Hospital Basel, Basel, Switzerland; Department of Clinical Research, University of Basel, Basel, Switzerland), Sara Droz (Universität Bern, Institut für Infektionskrankheiten, Bern, Switzerland), Alexis Dumoulin (Infectious Diseases Department, Central Institute of Hospitals, Sion, Switzerland), Stéphane Emonet (Infectious Diseases Department, Central Institute of Hospitals, Sion, Switzerland), Andrée Friedl (Infektiologie und Infektionsprävention, Kantonsspital Baden, Baden, Switzerland), Urs Führer (Spitalzentrum Biel, Biel, Switzerland), Christian Garzoni (Department of Internal Medicine, Clinica Luganese Moncucco, Switzerland), Valentin Gisler (Institute for Laboratory Medicine, Cantonal Hospital Aarau, Switzerland; Department for Infectious Diseases and Infection Prevention, Cantonal Hospital Aarau, Aarau, Switzerland), Christine Gutmann (Kantonsspital Winterthur, Winterthur, Switzerland), Gilbert Greub (Institute of Microbiology, University of Lausanne, Lausanne, Switzerland; University Hospital Center, Lausanne, Switzerland), Eva Hitz(Institute for Laboratory Medicine, Cantonal Hospital Aarau, Aarau, Switzerland), Philipp Kaiser (Luzerner Kantonsspital, Luzern, Switzerland), Peter Keller (Universität Bern, Institut für Infektionskrankheiten, Bern, Switzerland), Jörg D. Leuppi (Medizinische Fakultät Universität Basel, Basel, Switzerland; Medizinische Universitätsklinik Kantonsspital Baselland, Liestal, Switzerland), Reto Lienhard (ADMED Microbiology, La Chaux-de-Fonds, Switzerland), Irena Mitrović (Luzerner Kantonsspital, Luzern, Switzerland), Matthaios Papadimitriou-Olivgeris (Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland), Roberta Petrino (Emergency Medicine Department, Ente Ospedaliero Cantonale, Lugano, Switzerland), Benjamin Preiswerk (Infektiologie, Stadtspital Zürich, Zürich, Switzerland), Martin Risch (Cantonal Hospital Graubünden, Chur, Switzerland), Jacques Schrenzel (Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Genève, Switzerland; Bacteriology Laboratory, Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Genève, Switzerland), Brigitte J. Suter Buser (Luzerner Kantonsspital, Luzern, Switzerland), Philip E. Tarr(University Department of Medicine and Infectious Diseases Service, Kantonsspital Baselland, University of Basel, Basel, Switzerland), Maria Christine Thurnheer (Inselspital, Bern University Hospital, Bern, Switzerland), Mikaël Tognon (Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Genève, Switzerland; Bacteriology Laboratory, Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Genève, Switzerland), Laura Uccella (Emergency Medicine Department, Ente Ospedaliero Cantonale, Lugano, Switzerland), Miriam Vazquez (Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zürich, Switzerland), Alexander Wepf (Kantonsspital Winterthur, Winterthur, Switzerland), Benedikt Wiggli (Infektiologie und Infektionsprävention, Kantonsspital Baden, Baden, Switzerland)
Data Availability
Not applicable, as the manuscript constitutes a research protocol.
